Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma

Takuji Okusaka, Shuichi Okada, Hiroshi Ishii, Masafumi Ikeda, Hidekazu Nakasuka, Hiroyasu Nagahama, Ryoko Iwata, Hiroyoshi Furukawa, Kenichi Takayasu, Yukihiro Nakanishi, Michiie Sakamoto, Setsuo Hirohashi, Masayoshi Yoshimori

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Zinostatin stimalamer (SMANCS) is a lipophilic intra-arterial chemotherapeutic agent for hepatocellular carcinoma (HCC). Thirty HCC patients underwent transcatheter arterial injection of 4 mg SMANCS-lipiodol emulsion. Their responses were evaluated by computed tomography 1 month after treatment. Complete response (CR) was defined as disappearance or 100% necrosis of all tumors. Partial response (PR) was defined as @? 50% reduction and/or @? 50% necrosis. We regarded the lipiodol accumulation in tumors as being necrotic. CR and PR were observed in 8 patients (27%) and 4 patients (13%), respectively, and the overall response rate (CR + PR/all patients) was 40% (12/30). Of 12 patients whose serum α-fetoprotein levels had been more than 200 ng/ml before treatment, 5 patients (42%) showed more than 50% reduction in this level within 1 month after treatment. Toxicity was quite acceptable, although grade 4 toxicity (WHO) was observed as liver dysfunction in 1 patient. Transarterial chemotherapy with SMANCS, which is well tolerated, appears to have moderate antitumor effect in patients with HCC.

Original languageEnglish
Pages (from-to)276-283
Number of pages8
Issue number4
Publication statusPublished - 1998 Jul
Externally publishedYes


  • Hepatocellular carcinoma
  • Transarterial chemotherapy
  • Zinostatin stimalamer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Transarterial chemotherapy with zinostatin stimalamer for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this